Demand Fundamental	Value	Score	Rating
Qtr/Qtr Revenue Growth	Members Only
Qtr/Qtr Earnings Growth	Members Only
Year/Year Revenue Growth	Members Only
Year/Year Earnings Growth	Members Only
Multi-Year Revenue Growth	Members Only
Multi-Year Earnings Growth	Members Only
Relative PE Ranking	Members Only
Return on Equity	Members Only
Yield	Members Only
Institutional Holding	Members Only
Stock Price	Members Only
Relative Fundamental Ranking	Members Only
Total Score	Members Only

Demand Technical	Value	Score	Rating
Recommended Condition	Members Only
Trading Zone	Members Only
Average Trading Volume	Members Only
Industry Bull/Bear Condition	Members Only
Sector Bull/Bear Condition	Members Only
Current Signal Start Date	Members Only
Total Score	Members Only

AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue. Its primary product line includes isolator synergy bipolar radio-frequency ablation clamps for open-heart procedures and minimally invasive procedures- ablation and sensing unit, a compact power generator that delivers bipolar radio-frequency (RF) energy- AtriCure switch box, a compact switch box providing the technology needed for the dual pulsing electrodes, and the ability to connect and toggle between multiple RF devices- isolator multifunctional pen, a disposable RF device enabling surgeons to toggle back and forth between temporary pacing, sensing, and stimulation and ablation- and coolrail linear ablation device, a disposable linear RF ablation device, which allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. The company also offers cryoablation system, which consists of various reusable and disposable devices, including the Frigitronics CCS-200 product line for cardiac ablation- and Cryo1, a disposable cryoablation device, as well as AtriClip system, which is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures from the outside of the heart. In addition, it sells enabling technologies, including Lumitip dissector to separate tissues to provide access to key anatomical structures targeted for ablation- and MicroPace ORLab system, a stimulating, mapping, and recording system enabling physicians to confirm the ablation lines being created are forming electrical barriers or lines of block. The company sells its medical devices to hospitals and medical centers in the United States and internationally. AtriCure, Inc. is headquartered in West Chester, Ohio.